FibroSURE™and FibroScan®in relation to treatment response in chronic hepatitis C virus
Open Access
- 1 January 2011
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 17 (41), 4581-9
- https://doi.org/10.3748/wjg.v17.i41.4581
Abstract
To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan(®) transient elastography (TE) was performed during treatment in a patient subset. Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P < 0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P < 0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.Keywords
This publication has 38 references indexed in Scilit:
- Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1Gastroenterology, 2010
- An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpectII) during albinterferon alfa-2b combination therapy for chronic hepatitis CJournal of Viral Hepatitis, 2009
- Changes of non-invasive markers and FibroScan values during HCV treatmentJournal of Viral Hepatitis, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver diseaseGut, 2007
- Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patientsJournal of Hepatology, 2007
- Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis CGastroenterology, 2005
- Sources of variability in histological scoring of chronic viral hepatitisHepatology, 2005
- Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirinHepatology, 2003
- Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.2003